Crossmark

Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review

Crossref DOI link: https://doi.org/10.1007/s00228-024-03794-3

Published Online: 2024-12-23

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arabloo, Jalal

Rezaei, Mohammad Ali

Makhtoumi, Vahid

Sadiani, Zahra Mollaei

Rezapour, Aziz
License Information

Text and Data Mining valid from 2024-12-23

Version of Record valid from 2024-12-23
More Information

Article History

Received: 5 July 2024

Accepted: 18 December 2024

First Online: 23 December 2024

Declarations

:

: This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.1051).

: The authors declare no competing interests.

Document is current

Any future updates will be listed below